Nivalis Announces a First Dosing in Phase 2 Trial of Drug to Treat CF Patients with Specific Mutations

Nivalis Therapeutics announced the dosing of a first patient in a Phase 2 clinical trial evaluating the efficacy and safety of its investigational drug N91115, in combination with ivacaftor (Kalydeco), in people with cystic fibrosis (CF). CF is a life-shortening genetic disease, characterized by mutations in the CFTR gene that lead to defective chloride…

Protein Associated With Inflammation Surprisingly Repairs Common CF Mutation

Researchers at Institut national de la santé et de la recherche médicale (INSERM) in France have learned one way to “fix” cells that have characteristics of cystic fibrosis. These cells, which had faulty CFTR channel proteins, were able to make more functional CFTR protein following treatment with tumor necrosis…

New Combination Therapy May Treat 90% of All CF Patients

New ways of treating cystic fibrosis are under development at the University of Dundee. Along with colleagues in Italy, France, and Scotland, Dr. Anil Mehta, a clinical researcher at Dundee’s Medical Research Institute, pioneered a new drug combination that gives hope to patients with cystic fibrosis. “This work shows…